In translational work using high-grade serous ovarian cancer samples, tumors with mutations in BRCA1 or BRCA2 or other DNA damage response genes exhibited higher neoantigen load, CD3+ and CD8+ tumor-infiltrating lymphocytes, CD8+/CD4+ ratio, and PDL1 expression compared to those without mutated genes in the HR pathway [48]. The gene discussed is CD274; the disease is neoplasm.